ArticleJournal of inflammation research2025
Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cholestatic liver diseases, characterized by hepatic bile acid accumulation, often progress to fibrosis through incompletely understood mechanisms. While hydrophobic bile acids like glycochenodeoxycholic acid (GCDCA) are known to induce hepatocyte apoptosis or necrosis and their role in pyroptosis-a pro-inflammatory programmed cell death-remains unclear. This study investigates whether GCDCA drives hepatic stellate cell (HSC) activation via NLRP3 inflammasome-mediated pyroptosis in hepatocytes. Patients and Methods: Using L02 hepatocytes and LX2 HSCs, we evaluated the effects of GCDCA on NLRP3 inflammasome activation, gasdermin D (GSDMD)-dependent pyroptosis, and interleukin-1beta (IL-1β) secretion. Cells were treated with GCDCA (25-400 μM) ± lipopolysaccharide (LPS) to simulate cholestatic injury. Caspase-1 inhibition (Ac-YVAD-cmk), GSDMD knockdown (shRNA), and IL-1 receptor antagonist (IL-1RA) were employed to dissect mechanistic pathways. Pyroptosis (LDH release, Annexin V/PI staining), inflammasome components (NLRP3, ASC, caspase-1), GSDMD cleavage, IL-1β secretion (ELISA), and HSC activation (α-SMA, Collagen-I, proliferation/migration assays) were analyzed. Results: GCDCA alone upregulated NLRP3, pro-caspase-1, and pro-IL-1β in L02 cells but required LPS co-stimulation to trigger caspase-1 activation and GSDMD cleavage, indicating a dual-signal mechanism (priming + activation). This led to pyroptotic cell death (dose/time-dependent LDH release, Annexin V⁺/PI⁺ cells) and IL-1β secretion. GSDMD knockdown abolished pyroptosis and IL-1β release, while caspase-1 inhibition suppressed GSDMD-N-terminal (GSDMD-NT) generation. Conditioned media from pyroptotic hepatocytes activated LX2 HSCs, upregulating α-SMA and Collagen-I, and enhancing proliferation/migration-effects reversed by IL-1RA. Conclusion: GCDCA promotes HSC activation via NLRP3 inflammasome-mediated pyroptosis in hepatocytes, driven by caspase-1-dependent GSDMD cleavage and IL-1β paracrine signaling. This mechanism bridges bile acid toxicity to fibrogenesis, highlighting therapeutic potential for targeting NLRP3-GSDMD-IL-1β signaling in cholestatic liver diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.